


connections newsletter



**Oct 2018
UPDATE**

**Serving the NC Life
Sciences Industry**

<http://ncbioscience.net>
919-281-8960

[home](#) | [about](#) | [calendar](#) | [news](#) | [member benefits](#) | [forums](#) | [advocacy](#) | [contact](#)

NCBIO This Month

- One Week until NCBIO Annual Meeting
- Meeting with Congressman Holding on Medicare Part D
- A Range of Precision Medicine Topics at PMWC 2018 at Duke
- Informing Innovation 2018
- Bull City Biotech Summit 2018
- SEBIO Celebrates Its 20th Anniversary



- [At the National Level](#)
- [Member News](#)
- [Member Benefits](#)
- [Calendar](#)

NCBIO - Media

Find the latest news from NCBIO on the website ncbioscience.net, on [LinkedIn](#) and on Twitter at [@ncbio](#).

NCBIO Links

[CED](#)

[NCBIO](#)

[NC Biotech Center](#)

[BRITE](#)

[BTEC](#)


[BioNetwork](#)

[NCBioImpact](#)

[North Carolina
Pharmaceutical Services
Network](#)

[NCABR](#)

One Week until NCBIO Annual Meeting



OCTOBER 4, 2018

Big data and precision medicine will highlight this year's NCBIO Annual Meeting on October 4 at the NC Biotech Center in RTP. The program kicks off at 8:00 a.m. and ends with a networking lunch from 1:00 to 2:00 p.m. This year's event features three keynote speakers and two panel sessions focused on *How Big Data is Empowering Innovation* and *Precision-based Innovation*. Keynote speakers include:

NCBIO Sustaining Members

Biogen



- **Richard Staub** at IQVIA will provide a *State of the Industry* and bring attention to the shift of the product development pipeline, how big data is being used for identifying and developing targeted products, and how precision medicine is changing development and market dynamics for biotech and healthcare.
- **Paul Rudick** at Pfizer will speak to the *The Future of the BioPharma Industry* and highlight the emergence of a new class of therapy. He will discuss opportunities and limitations to gene therapy, its impact on the healthcare system, and how gene therapy is transformational for patients.
- **Anna Abram**, Deputy Commissioner for Policy, Planning, Legislation and Analysis, U.S. Food & Drug Administration, will deliver updates from FDA on Policies and Perspectives. Many NCBIO members know Ms. Abram for her previous work as a Senior Health Policy Advisor to Senator Richard Burr.

Thank you to our event sponsors.

- **Platinum:** [BIO](#), [Bioventus](#), [Cook Medical](#), and [VWR](#)
- **Gold:** [BDO](#), [Duke Energy](#), [FUJIFILM Diosynth Biotechnologies](#), [Novo Nordisk](#), and [Merz](#)
- **Silver:** [AdvaMed](#), [ALT](#), [IQVIA](#), [Mispro Biotech Services](#), [Office Depot](#), [ShareVault](#), [The Conafay Group](#), [UCB](#), and [UniFirst/UniClean](#)
- **Bronze:** [Business Wire](#), [G1 Therapeutics](#), [Grifols](#), [LiquidiaTechnologies](#), [Nikon](#), [Novozymes](#), and [Royal Hill Consulting](#)

For more information or to register, please visit the [event page](#) or contact [Amber Niebauer](#). Follow us on Twitter [#NCBIOAM](#).

[Back to top.](#)

Meeting with Congressman Holding on Medicare Part D



Randolph Cloud, Congressman Holding, Laura Gunter and Sam Taylor

NCBIO and We Work for Health representatives met with Congressman George Holding (R-NC 2nd District) regarding the need to repair problems w/ Medicare Part D arising from shortcomings of the Bipartisan Budget Act (BBA) of 2018.

NCBIO President Sam Taylor delivered a letter to Rep. Holding outlining concerns. "First, by shifting the share of Part D benefit plans' responsibility for so-called 'doughnut-hole' coverage from 25% to only 5%, the BBA nearly eliminates incentives for plans to compete with each other to provide low cost coverage. Such competition is essential to creating market-driven health care solutions that offer the most affordable,



Novartis



Pfizer



We Work For Health



NCBIO Supporting Members

Cook Medical



GSK



Merck



patient-centered healthcare options.”

Taylor noted, “Part D beneficiaries will also be hurt by the BBA’s failure to address the looming “out-of-pocket cliff” that, in 2020, will increase by \$1500 the amount beneficiaries must pay before achieving eligibility for Part D’s catastrophic benefit. Under this scenario, which will come to pass unless Congress acts, Part D beneficiaries’ out-of-pocket maximum will increase to \$6500 – not to mention the cost of Part D plan premiums.”

“Finally, the BBA’s impact on North Carolina’s economy will be substantially greater than most other states. Thanks to years of dedicated economic development efforts, North Carolina is the nation’s second largest producer of pharmaceuticals. Our pharmaceutical and biologics industry employs more than 20,000 workers with an average wage of more than \$98,000 per year. Unfortunately, our great strength in pharmaceutical manufacturing means North Carolina is disproportionately impacted by policies that penalize pharmaceutical companies. Thus, the BBA provisions increasing pharmaceutical manufacturers’ share of Part D ‘doughnut-hole’ costs from 50% to 70% put North Carolina’s pharmaceutical jobs and wages at risk,” Taylor stated.

After the meeting, Taylor stated that Holding had already stated his support for repairing Part D in a GOP leadership sign-on letter originally authorized by North Carolina Congressman Richard Hudson. “We found Congressman Holding very sympathetic to our concerns,” said Taylor. “I am hopeful that the House of Representatives will address this issue before adjourning later this year. Of course, any such solution will also require action by the Senate, where there is a great deal more uncertainty.”

[Back to top.](#)

A Range of Precision Medicine Topics at PMWC 2018 at Duke



Craig Venter

Craig Venter of J. Craig Venter Institute was opening keynote speaker at PMWC 2018 at Duke. Venter, who was involved with the first sequencing of the human genome, discussed new directions in research. Blue Cross Blue Shield NC CEO, Dr. Patrick Conway, told conference participants that precision medicine can improve health care and lower costs.

Rich West, CEO of Baebies, Inc., outlined how technology, policy and a business model are necessary for real innovation progress in precision diagnostics. Art Pappas of Pappas Capital shared the investment perspective in precision medicine. The two-day event spotlighted the explosion of biomedical technologies, driving initiatives that enable the translation of precision medicine into direct improvements in health care.

[Back to top.](#)

Informing Innovation 2018

Informing Innovation 2018

Expand your knowledge of the strategies, resources and trends in scientific and business content

Get up to speed in market research techniques, patent searching, copyright compliance, industry tools and much more, so your company is better equipped to innovate. Attend [Informing Innovation 2018](#), hosted by Life Science Intelligence at [NCBiotech](#), and expand your knowledge of the strategies, resources and trends in scientific and business content. The event is October 5, 9:00 a.m. – 3:00 p.m.

Keynote Panel

ROI Redefined: The Return on Information in Life Science Businesses

What challenges do companies, investors and consultants encounter when using information to drive their companies forward? What solutions have they found, and what are their go-to resources? Hear different perspectives on the value of good information in guiding key business decisions and in telling companies' stories.

Panelists

Dr. Blake Long, M.D., MBA, President, Long Health Care Consulting
Kyle Chenet, CEO, 410 Medical
Susan Acker-Walsh, Managing Partner, CREO

[Click](#) for the full agenda and to register.

[Back to top.](#)

Bull City Biotech Summit 2018



The event, October 10, 10 a.m. – noon at Durham Technical Community College, will provide a forum to connect Durham life science industry leaders to community resources and promote collaboration with the college and North Carolina Central University programs.

The focus is a sustainable workforce. Learn more about the programs and resources already available to your organization. Find out about recruitment initiatives, advanced training programs, customized training and funding available to offset your costs.

- Learn from employers that have successful programs in place.
- Hear about recruitment, placement, apprenticeship and internship opportunities.
- Hear from local academic institutions and their new Biotechnology, Advanced Manufacturing, BRITE, and NIIBML initiatives.

[Find out more.](#)

[Back to top.](#)

SEBIO Celebrates Its 20th Anniversary

Celebrating its 20th anniversary, the [Southeast BIO Investor & Partnering Forum](#) returns to Atlanta on November 13-14 at the Lowes Hotel with a new format, new networking opportunities, and new investment prospects. More than 300 biotech and medtech investors, corporate executives, university representatives, and entrepreneurs will attend the event this year. This is a rich opportunity to showcase your company at the most significant annual life science conference in the Southeast.

To date, more than 220 late stage and 180 early stage companies that participated in previous SEBIO Investor & Partnering Forums have raised more than \$2.5 billion in public and private funding. The SEBIO Forum Features:

- Executives, entrepreneurs, venture capitalists, investment bankers, angel investors, university representatives, and other industry professionals from across the Southeast and Eastern U.S.
- Presentations from the region's most promising life science and medtech companies
- The ability to arrange one-on-one meetings through the SEBIO Connect online partnering system
- World-class speakers and panels featuring engaging conversations by industry leaders
- Corporate Partnering discussions on approaches and strategic areas of interest with senior industry executives

[Click](#) for more information and to register.

[Back to top.](#)

At the National Level

BIO Applauds Legislation to Spur Investment in Start-ups

The Biotechnology Innovation Organization ([BIO](#)) applauded the introduction of the American Innovation Act of 2018 (H.R. 6756), which includes a provision that would protect investments in start-ups from inadvertently triggering the net operating loss (NOL) limitations under Section 382 of the tax code. R&D-intensive biotech start-ups frequently accumulate substantial NOLs in their early, pre-revenue years, given their typical reliance on investor capital for more than a decade before realizing any product revenue. [More](#)

Blueprint for Breakthroughs - Charting the Course for Precision Medicine

Commissioner Scott Gottlieb says the FDA is "taking steps to advance effective diagnostics that help reduce uncertainty and target effective care." In a recent speech, the Commissioner stated, "As clinical testing gets more and more sophisticated, we need to make certain that we have the right regulatory framework in place to ensure that these new clinical tests—including ones that we cannot even envision today—are accurate, reliable, and safe. And that these tests are made accessible to patients as soon as possible." [More](#)

AdvaMed Applauds Senate for Recognizing Role of Medical Technology to Help Combat Opioid Epidemic

AdvaMed President and CEO Scott Whitaker stated, "AdvaMed applauds the Senate action to move forward this important legislation to address the nation's opioid crisis. The bill includes provisions to provide a clear and efficient approval pathway for new

devices that can serve as alternative treatment solutions, and it also encourages beneficiary and provider education on non-opioid alternatives to treat pain. These provisions will help ensure that necessary medical technologies are available for patients." [More](#)

17th Annual BIO Investor Forum – October 17-18

BIO has unveiled programming for its upcoming [BIO Investor Forum](#) to be held October 17-18 at the Westin St. Francis Hotel in San Francisco. As an NCBio member, you can save \$200. Contact [Laura Gunter](#) to get your discount code for the savings.

The list of panel discussions will fall into business/public policy or therapeutic topics. Detailed descriptions can be found on [BIO's website](#).

Over 170 companies will deliver 15-minute presentations on their technology and product pipelines and approximately 2,700 meetings will be scheduled through BIO's One-on-One Partnering™ putting emerging companies in the best position to strike a deal or make connections for future discussions.

Preceding the opening of the BIO Investor Forum will be the SPARK Showcase sponsored by the SPARK Program in Translational Research at Stanford Medicine which aims to advance new biomedical research discoveries into new treatments for patients. The program and reception will run from 1:00 p.m. to 6:30 p.m. (PT). More information can be found [here](#).

[Back to top.](#)

Member News

To be included in Member News, send information about your organization to Brenda Summers bsummers@ncbioscience.net

NCBio members - [BASF](#), [Chiesi USA, Inc.](#), [DPR Construction](#), [G1 Therapeutics](#), and [United Therapeutics](#) were among the companies named by *Triangle Business Journal* as the "2018 Best Places to Work." [More](#) Rahshek Ellis of [Syngenta](#), Shelley Westman of [EY](#) and Courtney White of [BASF](#) were among the individuals receiving "2018 Leaders in Diversity Awards" from *Triangle Business Journal*. [More](#) 2018 Innovation Business Awards include: Jeffrey Lawson of [Humacyte](#), [BioLabs North Carolina](#) and [Renovion](#). [More](#)

[Aerie Pharmaceuticals, Inc.](#) announced that David W. Gyska has been appointed to the Company's Board of Directors and will also be a member of the Audit Committee of the Board. David brings extensive executive level healthcare-focused and financial leadership experience from large global biopharmaceutical firms. The company announced the appointment of Robert Finan, Director of Finance, reporting to Christopher Staten, Vice President of Finance. [More](#) Thomas Shepard has been appointed as Vice President, Implant Manufacturing, reporting to Casey Kopczynski, Ph.D., Aerie's Chief Scientific Officer. Mr. Shepard will lead Aerie's implant manufacturing facility in Durham, including responsibility for the development, manufacture and global supply of Aerie's ophthalmic drug-eluting implants. [More](#)

Steve Joseph and David Mosley have joined [ALT](#) as Vice President of Business Development and Director of Business Development, respectively. The two were previously with [ShareVault](#).

[BioCryst Pharmaceuticals, Inc.](#) announced that the Centers for Disease Control and Prevention (CDC) has awarded BioCryst a \$34.7 million contract for the procurement of up to 50,000 doses of BioCryst's approved antiviral influenza therapy, RAPIVAB® (peramivir injection) over a five-year period. "We appreciate the CDC acknowledging the value of RAPIVAB to patients and our national security," said Jon Stonehouse, Chief Executive Officer of BioCryst. [More](#) The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has awarded BioCryst an additional \$3.5 million to support clinical trials of galidesivir in patients with yellow fever. [More](#)

[Biogen](#) announced the enrollment of the first patient in the global Phase 3 clinical study CHARM, designed to evaluate BIIB093 (intravenous (IV) glibenclamide) for the prevention and treatment of severe cerebral edema in large hemispheric infarction (LHI), one of the most severe types of ischemic stroke where brain swelling (cerebral

edema) often leads to high morbidity and mortality. [More](#)

[G1 Therapeutics, Inc.](#) announced the closing of an underwritten public offering of 3,450,000 shares of its common stock at a public offering price of \$60.00 per share, including 450,000 shares sold pursuant to the full exercise of the underwriters' option to purchase additional shares. G1 Therapeutics received approximately \$195.1 million in proceeds from the offering, net of underwriting discounts and commissions, but before estimated offering expenses. [More](#) The company also announced that Garry Nicholson has been appointed to its board of directors, effective September 12th. "We are pleased to welcome Garry as an independent director to our board. He has a breadth of experience in oncology development and commercialization, including leading the global regulatory and launch strategy for the first CDK4/6 inhibitor approved in the U.S. and Europe. We look forward to his contributions as we advance our pipeline of innovative therapies to improve the lives of those affected by cancer," said Mark Velleca, M.D., Ph.D., Chief Executive Officer. [More](#)

[Grifols](#) announced that the U.S. Food and Drug Administration (FDA) has approved a new formulation of its GamaSTAN® immune globulin (human) for hepatitis A virus (HAV) and measles postexposure prophylaxis. GamaSTAN® is now available to healthcare providers across the country. "Vaccination, while a valuable option for hepatitis A and measles postexposure prophylaxis, may take several weeks to take effect as your immune system works to build the antibodies it needs to fight these viruses," said Dr. Stephen Scholand, Infectious Disease Specialist at MidState Medical Center. "Immune globulins such as GamaSTAN® have been a valuable treatment option for many decades because they offer immediate and rapid protection with antibodies that fight infection." [More](#)

[Mispro Biotech Services](#), a preclinical services company offering vivarium solutions for in-vivo science, announces the completion of a major renovation of its multi-user research facility in Research Triangle Park. The six-month project added 10 state-of-the-art rooms to its existing 25,000-square-foot facility, primarily to handle the demand Mispro was seeing from North Carolina's globally recognized biopharma and life sciences research community. [More](#)

[Back to top.](#)

NCBIO Member Benefits – New Discounts from NCBIO Member Companies



[BIO Business Solutions](#)® provides NCBIO members with numerous discount prices.

With more than \$350 million in annual sales, BIO Business Solutions® aggregates the purchasing power of over 3,000 life science companies from North America. Find out more about [NCBIO discounts](#).

[Office Depot](#) offers members discounts on a range of products. Up to of 80% off MSLP on a core list of over 1,000 frequently ordered office, cleaning and breakroom supplies. NCBIO has received significant savings on printing and copying services.

- Deep discounts on copy, print and finishing services
- More than 90,000 items discounted below retail
- Exclusive discounts on HP ink & toner
- Flexibility to customize to fit your needs
- Free delivery on qualifying orders
- Exclusive member promotions
- Same great price online or in-store
- Dedicated account management

For more information contact, Regina Winebarger, Business Development Manager, 336-803-2104 or regina.winebarger@officedepot.com

NCBIO members can realize savings through pre-negotiated rates from [UPS](#). BIO Business Solutions® brings you savings of up to 65% on UPS Worldwide International services. With a service area covering more than 220 countries and territories throughout the world, UPS brings speed, reliability, scalability and security to your global life sciences logistics needs.

UPS offers a wide selection of international shipping options to meet your time-definite and day-definite delivery requirements. Services range from UPS Worldwide Express to UPS Worldwide Expedited and more, in addition to value-added services such as ambient and temperature sensitive shipping, delivery confirmation, special handling options, and shipment consolidation to simplify customs clearance.

If you are new to UPS, visit savewithups.com/bio to complete the easy online enrollment, and begin realizing the benefits of shipping with UPS. If you're an existing UPS customer, contact your UPS Account Representative.

[Back to top.](#)

Calendar

To view full calendar, [click](#).

[Clinical Trial Supply Southeast 2018](#)

Tuesday Oct 2, 2018 - Wednesday Oct 3, 2018

... [read more](#)

[NCBIO Annual Meeting 2018](#)

Thursday Oct 4, 2018

... [read more](#)

[LaunchBio's "Larger Than Life Science" Monthly Networking Event](#)

Thursday Oct 4, 2018

... [read more](#)

[NCBiotech's Informing Innovation 2018](#)

Friday Oct 5, 2018

... [read more](#)

[2018 Ninth Annual North Carolina ACS CAN Research Breakfast](#)

Tuesday Oct 9, 2018

... [read more](#)

[Bull City Biotech Summit 2018](#)

Wednesday Oct 10, 2018

... [read more](#)

[The Fast-Track: Careers in Regulatory Science, Hosted by NCRAF and LaunchBio](#)

Thursday Oct 11, 2018

... [read more](#)

[Clinical Trial Supply East Coast 2018](#)

Tuesday Oct 16, 2018 - Wednesday Oct 17, 2018

... [read more](#)

[BIO Investor Forum](#)

Wednesday Oct 17, 2018 - Thursday Oct 18, 2018

... [read more](#)

[2018 SciTech Lecture Series: New Medical Discovery](#)

Thursday Oct 18, 2018

... [read more](#)

[NCABR Bridging the Gap](#)

Tuesday Oct 23, 2018 - Wednesday Oct 24, 2018

... [read more](#)

[NU Tech's AgBiotech Roundtable](#)

Tuesday Oct 23, 2018

... [read more](#)

[ASAP RTP Chapter: Cybersecurity and Privacy in the Collaborative Economy](#)

Tuesday Oct 23, 2018

... [read more](#)

North Carolina Biosciences Organization © copyright 2018

email: bsummers@ncbioscience.org phone: 919-281-8960 web: <http://ncbioscience.net>



NCBIO
P.O. Box 14354
Research Triangle Park
North Carolina 27709

